Skip to main content
Clinical Trials/NCT04783649
NCT04783649
Unknown
Not Applicable

Clinical Validation of Cervical Cancer Screening Methods in St. Petersburg, Russia

N.N. Petrov National Medical Research Center of Oncology1 site in 1 country2,500 target enrollmentJuly 13, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cervical Cancer
Sponsor
N.N. Petrov National Medical Research Center of Oncology
Enrollment
2500
Locations
1
Primary Endpoint
Sensitivity
Last Updated
5 years ago

Overview

Brief Summary

This single-institution cross-sectional non-inferiority validation study evaluates alternative techniques and tests for primary cervical cancer screening programs in Russia, particularly: local cytology staining techniques, local HPV tests.

Detailed Description

Cervical cytology practices are different across the world. While the Pap test became the cornerstone of the highly-effective cervical cancer screening in the countries that initially implemented population-based programs in the 60s and the 70s, alternative staining techniques were implemented in the Soviet Union. The tradition to apply other staining techniques than conventional Pap test remained unchanged in the national screening program implemented in the 2010s in Russia. As a new alternative option HPV testing showed effectiveness in screening women older than 30. The acceptable sensitivity and specificity of a screening test are crucial in population-based screening, that is why validation against "the gold standard" should be the first step in the process of program implementation. The objective of this study is to evaluate alternative techniques and tests for primary cervical cancer screening programs in Russia, particularly: local cytology staining techniques, local HPV tests in the population of 25-65 yo women without prior history of malignancy referred to colposcopy enriched with a population sample of women from several primary healthcare facilities referred to a primary screening test.

Registry
clinicaltrials.gov
Start Date
July 13, 2020
End Date
July 1, 2023
Last Updated
5 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
N.N. Petrov National Medical Research Center of Oncology
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age between 25 and 65 years old Referral to colposcopy or to a primary screening test Signed informed consent

Exclusion Criteria

  • Prior history of malignancy or cervical dysplasia Prior history of cervical dysplasia

Outcomes

Primary Outcomes

Sensitivity

Time Frame: 24 months

Cervical screening tests sensitivity

Specificity

Time Frame: 24 months

Cervical screening tests specificity

Secondary Outcomes

  • Cervical dysplasia prevalence(24 months)
  • HPV prevalence by type(24 months)

Study Sites (1)

Loading locations...

Similar Trials